Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its selective PARP1 inhibitors EIK1003 and EIK1004, and WRN helicase inhibitor EIK1005 at the 2026 ESMO Congress. EIK1003 showed a favorable safety profile and signs of antitumor activity both as monotherapy and in combination with other cancer treatments. EIK1004 demonstrated good tolerability with minimal severe blood-related side effects, while EIK1005 showed promising stability and response in patients with specific tumor types. Additional data and combination studies are expected in 2027, supporting Eikon's progress in developing innovative cancer therapies.
Eikon Therapeutics' cancer drug programs are the subject, with Pluang data showing 28 of 150 Health-sector US stocks rose while 119 fell today. For readers following Health stocks, here is Pluang's market snapshot as of Oct 23, 2026 20:21 WIB: BTSG traded at USD 60.01 with a 1-day change of -1.40% and a typical hold time of 14 days; DYN was at USD 15.55, down 1.40%, with 100% sell order activity and a 4-day hold time; INO rose 1.32% to USD 0.85 with 73% sell and 27% buy order activity and a typical hold time of 43 days.
FS Bancorp, Inc. has appointed Matthew D. Mullet as a director on the boards of both the company and its bank, 1st Security Bank of Washington, effective October 22, 2026. Mullet, who has been President since 2024 and CEO since 2025-2026, brings exte...
The global protein ingredients market, valued at $42.3 billion in 2025, is projected to grow to $65 billion by 2032 with a CAGR of 6.3%. Growth is driven by rising consumer demand for health-focused, protein-enriched foods, sports nutrition, and sust...
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
